STEMIs and Coumadin: Are they an unsafe combination?

Jana E Montgomery Michael S Levy

Published in: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2020)

Therapeutic anticoagulation may be a surrogate marker for increased MACE in the setting of a STEMI. Consideration should be given to transradial access for patients on anticoagulation. Triple therapy (DAPT plus anticoagulant) should be minimized.

Keyphrases

atrial fibrillation
venous thromboembolism
end stage renal disease
percutaneous coronary intervention
ejection fraction
chronic kidney disease
newly diagnosed
peritoneal dialysis
stem cells
st segment elevation myocardial infarction
mesenchymal stem cells
bone marrow
cell therapy
replacement therapy